I've watched a horde of nasty bad bashers over on the VVUS board proclaiming how much better Belviq is than Qsymia, but seriously folks, there are plenty of fat people on the planet to make both companies **RICH**. After all, that is what we are after right? Well, that and to mess-over the shorts!
Race you to $100 SHARE - may it be a VERY close race & us ALL get RICH!
I have long advocated that both drugs will be successful and both companies will profit. The horse race scenario was not, and is not useful. Even companies like Jennie Craig and Weight Watchers could benefit by incorporating awareness of these drugs to their member/customers and embracing the use of drugs to augment their healthy procedures.
But the other side of the coin is that some people who are investors like to see that their choices of investments were the ONLY right ones, and try to protect those choices by bashing the others. Too bad, I, for a while, was invested in both ARNA and VVUS, but decided that because this winner-take-all attitude prevailed, to invest in both could become a zero-sum game, so decided to go with science correctness rather than marketing correctness. I.e Arena knows why Belviq works having DESIGNED the drug to ineract with the hypothalamus recepts and to avoid the fen-Phen problem, and Vivus knows how to promote Qysemia and found it by lucky combination of known drugs. Vivus has been more effective in their PR program leading up to FDA approval than Arena, but being an engineer, I like to think at least that science will eventually trump hype.
AND together we can trash the short-selling parasites like the #$%$ that they are.
I think that there are tradeoffs for both Belviq and Qsymia. There are very strong arguments to be made for both. Seriously, if there is a big market for both COKE and PEPSI then certainly there is plenty of market for both Belviq and Qsymia.